<unk> ® is a test developed to evaluate patient prognosis and, additionally, predict benefit from cancer treatment by EGFR inhibitors. It is a serum/plasma proteomic test developed using matrix-assisted laser desorption/ionization (MALDI) mass spectrometry.<unk>  was developed by Biodesix, Inc., a molecular diagnostics company based in Boulder, CO, USA. The<unk>  algorithm has been interrogated retrospectively and prospectively in samples from randomized trials, such as the PROSE study, confirming the prognostic information associated with the molecular signature. In addition, the test appeared to be predictive of erlotinib impact on survival, as only<unk>  Good patients" benefited from such a treatment. Additional studies have confirmed its clinical relevance.
Veristrat
Suvorexant
Influenzanet
Icatibant
Mitapivat
Patiromer
Befetupitant
Daridorexant